About Nucleus Genomics
Nucleus Genomics is a company based in Manhattan (United States) founded in 2021 by Kian Sadeghi. Nucleus Genomics has raised $31.5 million across 3 funding rounds from investors including Neo, Seven Seven Six and Balaji Srinivasan. Nucleus Genomics has completed 2 acquisitions, including Cambrean and Impute.me. Nucleus Genomics offers products and services including DNA Health Test and Whole-Genome Test. Nucleus Genomics operates in a competitive market with competitors including ArcherDX, Natera, Variantyx, ImaginAb and RareCyte, among others.
- Headquarter Manhattan, United States
- Founders Kian Sadeghi
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nucleus Genomics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nucleus Genomics
Nucleus Genomics offers a comprehensive portfolio of products and services, including DNA Health Test and Whole-Genome Test.
Analyzes genetic risks for over 900 health conditions including cancers.
Sequences full genome for insights on diseases and longevity factors.
People of Nucleus Genomics
Unlock access to complete
Funding Insights of Nucleus Genomics
Nucleus Genomics has successfully raised a total of $31.5M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nucleus Genomics
Nucleus Genomics has secured backing from 26 investors, including venture fund and angel investors. Prominent investors backing the company include Neo, Seven Seven Six and Balaji Srinivasan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on investing in technology startups
|
Locked | Locked | Locked | |
|
Technology startups are accelerated and incubated sector-agnostically by Neo.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in deep tech innovations.
|
Locked | Locked | Locked |
Investor details for Nucleus Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nucleus Genomics
Nucleus Genomics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cambrean and Impute.me.
Investment portfolio details for Nucleus Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Digital health analytics for businesses are provided via a platform.
|
Locked | Locked | 2021 | Locked | |
|
Non-profit tools utilizing data services are provided by Impute.me.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Nucleus Genomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nucleus Genomics
Detailed financials for Nucleus Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nucleus Genomics Comparisons
Peer comparison for Nucleus Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nucleus Genomics
Nucleus Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Natera, Variantyx, ImaginAb and RareCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Genetic sequencing is provided for late-stage cancer patients.
|
Detailed competitors of Nucleus Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nucleus Genomics
Complete news archive for Nucleus Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nucleus Genomics
Nucleus Genomics was founded in 2021.
Nucleus Genomics is headquartered in Manhattan, United States. It is registered at Manhattan, New York, United States.
Kian Sadeghi is the current CEO of Nucleus Genomics. They have also founded this company.
Nucleus Genomics is a funded company, having raised a total of $31.5M across 3 funding rounds to date.
Nucleus Genomics was established in 2021 in Manhattan, United States, within the genomics sector. A direct-to-consumer platform is operated, where whole-genome sequencing is utilized to deliver genetic risk and disposition score analyses. These services cover an extensive array of diseases and traits, with a focus on rare variant detection through at-home testing kits. Operations are centered on accessible genetic insights for individual users.
Nucleus Genomics's top competitors include Natera, ImaginAb and Lantern Pharma.
Nucleus Genomics offers DNA Health Test and Whole-Genome Test.
Nucleus Genomics has 26 investors. Key investors include Neo, Seven Seven Six, Balaji Srinivasan, Achal Upadhyaya, and Giant Step Capital.